C controlled trial of taurolin in established bacterial peritonitis.
Taurolin administered intraperitoneally has effected a significant reduction in morbidity in peritonitis even when all other methods of intensive care, including powerful antibiotics, have been used. Easy to use clinically, it is effective locally against all fecal pathogens and is nontoxic.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D013654:Taurine / Q000031:analogs & derivatives; D013829:Thiadiazines / Q000627:therapeutic use*; D013843:Thiazines / Q000627:therapeutic use*
D000891:Anti-Infective Agents, Local; D013829:Thiadiazines; D013843:Thiazines; D013654:Taurine; C012566:taurolidine